- Home
- Signaling Pathways
- GPCR/G protein
- Adrenergic Receptor
- Timolol Maleate
Timolol Maleate
Physical Appearance | A solid |
Storage | Store at -20°C |
M.Wt | 432.49 |
Cas No. | 26921-17-5 |
Formula | C17H28N4O7S |
Solubility | ≥21.62 mg/mL in DMSO; ≥10.53 mg/mL in EtOH; ≥11.83 mg/mL in H2O |
Chemical Name | (Z)-but-2-enedioic acid;(2S)-1-(tert-butylamino)-3-[(4-morpholin-4-yl-1,2,5-thiadiazol-3-yl)oxy]propan-2-ol |
SDF | Download SDF |
Canonical SMILES | CC(C)(C)NCC(COC1=NSN=C1N2CCOCC2)O.C(=CC(=O)O)C(=O)O |
Shipping Condition | Small Molecules with Blue Ice, Modified Nucleotides with Dry Ice. |
General tips | We do not recommend long-term storage for the solution, please use it up soon. |
Animal experiment:[1] | |
Animal models |
Adult male Wistar rats, 9 weeks of age, 250 ~ 300 g |
Dosage form |
0.5% timolol maleate Topically applied daily, started 1 week after the laser photocoagulation and lasted for 3 weeks |
Applications |
In rats subjected to intracameral injection of India ink and subsequent laser trabecular photocoagulation, timolol maleate induced a significant reduction in intraocular pressure (IOP) and counteracted the reduction in retinal ganglion cell (RGC) number that occurred in vehicle treated glaucomatous eyes. Thus, timolol maleate was able to reduce IOP and protected RGCs in a rat model of experimental glaucoma. |
Note |
The technical data provided above is for reference only. |
References: 1. Seki M, Tanaka T, Matsuda H, et al. Topically administered timolol and dorzolamide reduce intraocular pressure and protect retinal ganglion cells in a rat experimental glaucoma model. British Journal of Ophthalmology, 2005, 89(4): 504-507. |
Quality Control & MSDS
- View current batch: